Q4 2024 Lantheus Holdings Inc Earnings Call Transcript
Key Points
- Lantheus Holdings Inc (LNTH) achieved over $1 billion in sales for PYLARIFY, marking it as the first radiodiagnostic blockbuster.
- The company announced strategic transactions to enhance capabilities in Alzheimer's Diagnostics and Oncology Therapeutics, expected to drive double-digit revenue growth starting in 2026.
- CMS issued a rule enhancing payment for specialized diagnostic radiopharmaceuticals, supporting long-term innovation.
- DEFINITY, the market-leading ultrasound-enhancing agent, saw a 17.9% year-over-year increase in sales.
- Lantheus Holdings Inc (LNTH) reported a strong free cash flow of $493.1 million for the full year, with plans to expand it further in 2025.
- Operating expenses increased, with significant costs tied to business development activities and potential acquisitions.
- The company recorded an unrecognized loss of $119.1 million related to its equity investment in Radiopharm Theranostics.
- Gross profit margin decreased by 130 basis points year over year due to prior year royalty milestones.
- The strategic partnerships and other revenue segment saw a 66.2% decline in the fourth quarter.
- The guidance for 2025 indicates only a 1% to 5% increase in net revenue, reflecting potential challenges in maintaining high growth rates.
Good morning. Welcome to the Lantheus fourth quarter and full year 2024 conference call. (Operator Instructions) This call is being recorded, and a replay will be available in the Investors section of the company's website approximately 2 hours after the completion of the call. The call will be archived for at least 30 days.
I will now turn the call over to Mark Kinarney, Vice President of Investor Relations. Mark?
Thank you. Good morning. With me today are Brian Markison, our CEO; Paul Blanchfield, our President; Bob Marshall, our CFO; and Amanda Morgan, our Chief Commercial Officer. We will begin with prepared remarks and then open the call for Q&A.
This morning, we issued a press release, which was furnished to the SEC under Form 8-K, reporting our fourth quarter 2024 results. The release and today's slide presentation are in the Investors section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
